116 related articles for article (PubMed ID: 15894403)
41. Malignant mesothelioma 2008.
Zervos MD; Bizekis C; Pass HI
Curr Opin Pulm Med; 2008 Jul; 14(4):303-9. PubMed ID: 18520263
[TBL] [Abstract][Full Text] [Related]
42. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
Schmidt H; Suciu S; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; von der Maase H; Eggermont AM; Keilholz U; ;
J Clin Oncol; 2007 Apr; 25(12):1562-9. PubMed ID: 17443000
[TBL] [Abstract][Full Text] [Related]
43. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion.
Deraco M; Nonaka D; Baratti D; Casali P; Rosai J; Younan R; Salvatore A; Cabras Ad AD; Kusamura S
Ann Surg Oncol; 2006 Feb; 13(2):229-37. PubMed ID: 16444562
[TBL] [Abstract][Full Text] [Related]
44. A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma.
Zellos L; Richards WG; Capalbo L; Jaklitsch MT; Chirieac LR; Johnson BE; Bueno R; Sugarbaker DJ
J Thorac Cardiovasc Surg; 2009 Feb; 137(2):453-8. PubMed ID: 19185169
[TBL] [Abstract][Full Text] [Related]
45. [Diffuse malignant pleural mesothelioma].
Katsuragi N; Shiraishi Y; Kita H; Toishi M; Miyasaka Y; Tanaka S
Kyobu Geka; 2007 Jan; 60(1):35-9. PubMed ID: 17249536
[TBL] [Abstract][Full Text] [Related]
46. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
[TBL] [Abstract][Full Text] [Related]
47. Pemetrexed: a multitargeted antifolate.
Rollins KD; Lindley C
Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
[TBL] [Abstract][Full Text] [Related]
48. [Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases].
Tao ZF; Fu WJ; Chen YB; Yuan ZG; Wang DX; Hou J
Ai Zheng; 2006 Apr; 25(4):461-4. PubMed ID: 16613681
[TBL] [Abstract][Full Text] [Related]
49. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST
Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110
[TBL] [Abstract][Full Text] [Related]
50. EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma.
Edwards JG; Swinson DE; Jones JL; Waller DA; O'Byrne KJ
Lung Cancer; 2006 Dec; 54(3):399-407. PubMed ID: 17049671
[TBL] [Abstract][Full Text] [Related]
51. Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma.
Sterman DH; Albelda SM
Respirology; 2005 Jun; 10(3):266-83. PubMed ID: 15955137
[TBL] [Abstract][Full Text] [Related]
52. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
Flores RM; Pass HI; Seshan VE; Dycoco J; Zakowski M; Carbone M; Bains MS; Rusch VW
J Thorac Cardiovasc Surg; 2008 Mar; 135(3):620-6, 626.e1-3. PubMed ID: 18329481
[TBL] [Abstract][Full Text] [Related]
53. Malignant pleural mesothelioma: surgical management in 285 patients.
Schipper PH; Nichols FC; Thomse KM; Deschamps C; Cassivi SD; Allen MS; Pairolero PC
Ann Thorac Surg; 2008 Jan; 85(1):257-64; discussion 264. PubMed ID: 18154820
[TBL] [Abstract][Full Text] [Related]
54. Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy.
Kim JG; Ryoo BY; Park YH; Kim BS; Kim TY; Im YH; Kang YK
Cancer Chemother Pharmacol; 2008 Feb; 61(2):301-7. PubMed ID: 17429626
[TBL] [Abstract][Full Text] [Related]
55. [Treatment outcomes and prognostic analyses of relapsed or refractory T-cell non-Hodgkin's lymphoma].
Gao Y; Huang HQ; Lin XB; Cai QQ; Pan ZH; Wang BF; Bu Q
Ai Zheng; 2007 Aug; 26(8):909-13. PubMed ID: 17697558
[TBL] [Abstract][Full Text] [Related]
56. Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma.
Yan TD; Brun EA; Cerruto CA; Haveric N; Chang D; Sugarbaker PH
Ann Surg Oncol; 2007 Jan; 14(1):41-9. PubMed ID: 17039392
[TBL] [Abstract][Full Text] [Related]
57. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
Curran D; Sahmoud T; Therasse P; van Meerbeeck J; Postmus PE; Giaccone G
J Clin Oncol; 1998 Jan; 16(1):145-52. PubMed ID: 9440736
[TBL] [Abstract][Full Text] [Related]
58. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
Herndon JE; Green MR; Chahinian AP; Corson JM; Suzuki Y; Vogelzang NJ
Chest; 1998 Mar; 113(3):723-31. PubMed ID: 9515850
[TBL] [Abstract][Full Text] [Related]
59. Tumor necrosis correlates with angiogenesis and is a predictor of poor prognosis in malignant mesothelioma.
Edwards JG; Swinson DE; Jones JL; Muller S; Waller DA; O'Byrne KJ
Chest; 2003 Nov; 124(5):1916-23. PubMed ID: 14605068
[TBL] [Abstract][Full Text] [Related]
60. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems.
Edwards JG; Abrams KR; Leverment JN; Spyt TJ; Waller DA; O'Byrne KJ
Thorax; 2000 Sep; 55(9):731-5. PubMed ID: 10950889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
